Review of COVID-19 Therapeutics and Anti-Herpes Virus Drugs

Review Article

Abstract

This review provides an overview of the COVID-19 pandemic and anti-herpes virus drugs, focusing on their mechanisms of action, analytical methods, and recent developments. The SARS-CoV-2 virus, responsible for COVID-19, has prompted unprecedented global research efforts to develop effective therapeutics. We examine key FDA-approved drugs for COVID-19 treatment, including remdesivir, tocilizumab, anakinra, and dexamethasone, discussing their modes of action and analytical techniques used for their quantification. The review also explores the current landscape of anti-herpes virus drugs, primarily focusing on acyclovir, valacyclovir, and famciclovir. These drugs, crucial in managing herpes simplex virus (HSV) infections, are analyzed in terms of their pharmacological properties and the analytical methods employed for their detection and quantification. Recent advancements in drug development, including novel formulations and combination therapies, are highlighted. The review emphasizes the importance of accurate analytical techniques, such as HPLC, LC-MS, and spectrophotometric methods, in ensuring drug quality and efficacy